Both the pro-angiogenic activity of NRP-1 and its link to PARPi resistance would strongly suggest a potential use as a suitable auxiliary marker for predicting response to the combination of bevacizumab/olaparib in patients with ovarian cancer. Here, NRP1 is linked to ovarian carcinoma.